Trials / Not Yet Recruiting
Not Yet RecruitingNCT07338838
To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors
A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TQB3142 for Injection in Patients With Advanced Malignant Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To explore the safety, tolerability and pharmacokinetics of TQB3142 for injection in subjects with advanced malignant tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3142 injection | TQB3142 for injection is a B-cell lymphoma-extra large inhibitor. |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2027-12-01
- Completion
- 2028-06-01
- First posted
- 2026-01-14
- Last updated
- 2026-01-14
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07338838. Inclusion in this directory is not an endorsement.